If you are looking for some new additions to your portfolio, then the ASX 200 stocks listed below could be worth a closer look.
They have been named on Bell Potter's Australian Equities Panel for the month of July. These are the shares the broker believes "offer attractive risk-adjusted returns over the long term."
Bell Potter also highlights that they are "quality companies with proven track records, strong management teams and competitive advantages."
We have already covered two stocks on the list here. Let's now take a look at two more of the broker's top picks for the month:
Flight Centre Travel Group Ltd (ASX: FLT)
The team at Bell Potter remains positive on Flight Centre and sees it as one of the best ASX 200 stocks to buy now.
The broker feels that its shares are too cheap at current levels. Especially given its positive earnings growth outlook.
In light of this, Bell Potter sees potential for its shares to re-rate to higher multiples in the near future. It said:
With peak tariff uncertainty passed, we believe upside is not being priced into FLT. Trading at 10.8 12MF P/E and with an 18% EPS growth 2yr CAGR, there is potential for the stock to re-rate closer to its historical average. Continued cost out initiatives and growth in corporate TTV help de-risk its cyclical nature, and with more potential RBA rate cuts, increased consumer spending on travel in FY26 could be a key beneficiary.
ResMed Inc. (ASX: RMD)
Another ASX 200 stock that features on the list this month is ResMed.
It is the world's leading sleep disorder treatment company with a portfolio of world class hardware and software solutions.
Bell Potter believes that a de-rating of its shares has dragged them down to very attractive multiples and thinks investors should be snapping them up while they still can. Particularly given the size of the obstructive sleep apnoea (OSA) market opportunity. It explains:
The company commands a significant share of the global OSA homecare device market, which is predominantly a duopoly between ResMed and Philips Respironics (who remain under FDA consent decree that blocks new device sales in the US), with ResMed leading in many of the 140 countries it operates in. The OSA market is experiencing robust growth, driven by increasing awareness and diagnosis rates.
GLP-1 headlines knocked the 12MF P/E from ~32x to ~24x currently (which we view as being over-done), while earnings remain robust, with EPS 2yr CAGR of 11%, a strong balance sheet, and an FY256 ROE at 24%, presents an attractive opportunity, and our preferred way, of including defence into a portfolio.
